6.30
-0.94%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Abbisko Cayman
Its shares trade on HKEX under the ticker 2256.HK. It has been listed since 13 October 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥695.3m and net income of CN¥62.8m. At that date it held total assets of CN¥2.75bn and shareholders' equity of CN¥2.24bn.
Abbisko Cayman Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of drugs and small molecule oncology therapies. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-10-13. The firm is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The firm owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Company’s products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 13 Oct 2021
- Employees
- 252
- Website
- abbisko.com ↗
Leadership
Pay as last reported
- Mr. Yao-Chang XuExecutive Chairman of the Board Chief Executive Officer, Co-Founder, since 2018CN¥23.1m
- Mr. Hongping YuCo-Founder, Senior Vice President, Executive Director, Joint Company Secretary, since 2018CN¥17.1m
- Mr. Lin YeGroup Chief Financial Officer, Head - Strategic Operations, since 2020CN¥14.0m
- Dr. Zhen ZhangVice President, Head - Chemistry, Manufacturing and Controls
- Mr. Yongyi LiGeneral Counsel
- Ms. Jing JiExecutive Director, Chief Medical Officer, since 2021
- Dr. Kewei XieChief Business Officer
- Ms. Yin Wah ChanJoint Company Secretary
- Ms. Hoi Yam ChuiNon-Executive Independent Director
- Mr. Hongbin SunNon-Executive Independent Director
- Mr. Piaoyang SunNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Abbisko Cayman Ltd employs 252 full-time staff members dedicated to drug research.
- The firm owns two core product candidates named ABSK011 and ABSK091 for oncology.
- ABSK011 is a potent inhibitor of fibroblast growth factor receptor 4 for cancer.
Weaknesses
- The company is a clinical-stage biopharmaceutical firm with limited commercial products.
- Only twelve other pipeline candidates exist alongside the two core product options.
- Abbisko Cayman Ltd is headquartered in Shanghai, which may limit global reach.
Opportunities
- ABSK091 targets FGFR subtypes 1, 2 and 3 for urothelial cancer treatment.
- The firm develops therapies for hepatocellular carcinoma, a significant global health burden.
- Innovative small molecule oncology therapies offer potential growth in the biotechnology sector.
Threats
- Competitors in the biotechnology sector may develop superior FGFR inhibitors for cancer.
- Clinical trial results for ABSK011 and ABSK091 could fail to meet expectations.
- Regulatory hurdles in China and other markets may delay product approvals.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.